Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

NVGN:US

7.6300 USD 0.6900 9.94%

As of 20:10:00 ET on 04/17/2015.

Company Profile for Novogen Ltd (NVGN)

Novogen Limited is a drug discovery company. The Company owns two proprietary drug technology platforms which include super-benzopyrans and anti-tropomyosins that target broad therapeutic potential across the fields of cancer, musculodegenerative diseases, neurodegenerative diseases, regenerative medicine, lysosomal storage diseases, and autoimmune diseases.

Contact Information

Novogen Ltd

16 - 20 Edgeworth David Ave
Hornsby, NSW 2077
Australia
Phone: 61-2-9472-4100
Fax: 61-2-9476-0388

Key Executives for Novogen Ltd (NVGN)

Graham Edmund KellyChairman/CEODavid BrownChief Scientific Officer
Cristyn HumphreysCOO:Administration & FinanceW Andrew HeatonVP:Drug Discovery
Justine StehnDir:ATM ProgramStephen PalmerDir:Degenerative Disease Program
Lionel MateoSecretaryKimberley LilischkisManager:Clinical & Regulatory Affairs

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil